400748-70-1

Basic information

• Product Name: 3'-METHOXY-BIPHENYL-3-YLAMINE
• Synonyms: TIMTEC-BB SBB007485;CHEMBRDG-BB 4005743;AKOS BAR-0119;3'-METHOXY[1,1'-BIPHENYL]-3-AMINE;3'-METHOXY-BIPHENYL-3-YLAMINE;(3'-methoxybiphenyl-3-yl)amine(SALTDATA: HCl);3'-Methoxy-biphenyl-3-amine
• CAS NO: 400748-70-1
• Molecular Formula: C₁₃H₁₃NO
• Molecular Weight: 199.25
• Mol File: 400748-70-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 370.2 °C at 760 mmHg
• Flash Point: 190.6 °C
• Appearance: /
• Density: 1.1 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3'-METHOXY-BIPHENYL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3'-METHOXY-BIPHENYL-3-YLAMINE(400748-70-1)
• EPA Substance Registry System: 3'-METHOXY-BIPHENYL-3-YLAMINE(400748-70-1)

Safety Data

• Hazard Codes: Xi
• Statements: 41
• Safety Statements: 26-39
• HazardClass: IRRITANT
• Hazardous Substances Data: 400748-70-1(Hazardous Substances Data)

Usage

General Description

3'-Methoxy-biphenyl-3-ylamine, also known as 3-methoxy-3-phenylbiphenylamine, is an organic compound consisting of a biphenyl core with a methoxy group and an aniline moiety. It is a pale yellow solid that is commonly used as a chemical intermediate in the production of various pharmaceuticals and organic compounds. This chemical has applications in the synthesis of dyes, pigments, and polymers, as well as in the production of specialty chemicals. It is also used as a precursor in the pharmaceutical industry, particularly in the synthesis of certain drugs and pharmaceutical intermediates. Overall, 3'-Methoxy-biphenyl-3-ylamine is a versatile and important chemical compound with various industrial applications.

Upstream product

• 10365-98-7 3-methoxyphenylboronic acid 
• 591-19-5 m-Bromoaniline 
• 2398-37-0 3-methoxyphenyl bromide 
• 13331-27-6 m-nitrobenzene boronic acid 
• 67-56-1 methanol 
• 76629-45-3 3-methyl-5-(m-nitrophenyl)-1,2,4-oxadiazole 
• 121-92-6 3-nitrobenzoic acid 
• 128923-93-3 1‐(3‐methoxyphenyl)‐3‐nitrobenzene 
• 626-01-7 3-Iodoaniline 

Downstream Products

• 849061-05-8 cyclohexylcarbamic acid 3'-benzyloxycarbonylaminobiphenyl-3-yl ester 
• 779341-21-8 (3'-hydroxybiphenyl-3-yl)carbamic acid benzyl ester 
• 779341-19-4 3‘-amino-[1,1‘-biphenyl]-3-ol 

Relevant articles and documents

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Design, synthesis, and structure-activity relationship of 7-propanamide benzoxaboroles as potent anticancer agents

Benzoxaboroles, as a novel class of bioactive molecules with unique physicochemical properties, have been shown to possess excellent antimicrobial activities with tavaborole approved in 2014 as an antifungal drug. Although urgently needed, the investigation of benzoxaboroles as anticancer agents has been lacking so far. In this study, we report the design, synthesis, and anticancer structure-activity relationship of a series of 7-propanamide benzoxaboroles. Compounds 103 and 115 showed potent activity against ovarian cancer cells with IC50 values of 33 and 21 nM, respectively. Apoptosis was induced by these compounds and colony formation was effectively inhibited. Furthermore, they also showed excellent efficacy in ovarian tumor xenograft mouse model.

DIARYLUREAS AS CB1 ALLOSTERIC MODULATORS

The present invention provides novel diarylurea derivatives (compounds of formula (I)) and their uses. The compounds of the present invention are demonstrated to be allosteric modulators of the CB1 receptor, and therefore useful for the treatment of diseases and conditions mediated by CB1.